Zacks Research Reduces Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Analysts at Zacks Research cut their Q2 2025 earnings per share estimates for shares of Zimmer Biomet in a note issued to investors on Wednesday, June 25th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $1.97 for the quarter, down from their prior estimate of $1.98. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's FY2025 earnings at $7.91 EPS, FY2026 earnings at $8.05 EPS and FY2027 earnings at $8.59 EPS.

A number of other equities analysts also recently issued reports on the company. JMP Securities lowered their price target on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Robert W. Baird reduced their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Morgan Stanley dropped their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada dropped their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $91.93 on Friday. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. Zimmer Biomet has a 52 week low of $89.22 and a 52 week high of $116.71. The stock's 50-day moving average price is $94.77 and its 200-day moving average price is $102.38. The stock has a market capitalization of $18.19 billion, a PE ratio of 20.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The firm's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the business earned $1.94 earnings per share.

Institutional Trading of Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Zimmer Biomet by 0.7% in the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock worth $2,609,130,000 after acquiring an additional 166,763 shares during the period. Dodge & Cox grew its holdings in shares of Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider's stock worth $2,214,305,000 after purchasing an additional 446,018 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock worth $1,559,147,000 after purchasing an additional 176,337 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after buying an additional 2,796,372 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider now directly owns 20,424 shares of the company's stock, valued at $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.39% of the stock is currently owned by corporate insiders.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.04%. Zimmer Biomet's payout ratio is 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.